Business
Therma Bright Provides Update on Venowave for the United States and Texas Region
Toronto, Ontario--(Newsfile Corp. - June 30, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRI...
About this update from Therma Bright Inc.
[{"type":"text","content":"Therma Bright Provides Update on Venowave for the United States and Texas RegionToronto, Ontario--(Newsfile Corp. - June 30, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (\"Therma\" or the \"Company\"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announced that on May 31, 2023, representatives from Therma Bright Inc and the U.S. Department of Health and Human Services (DHHS) engaged in productive discussions regarding the significance and potential impact of securing unique permanent Current Procedural Terminology (CPT®) / Healthcare Common Procedure Coding System (HCPCS) codes for the innovative Venowave device. The final decision regarding the issuance of these unique CPT and HCPCS codes will be released by the Centers for Medicare and Medicaid Services (CMS) in August 2023. \"We greatly appreciate the collaboration with the U.S. DHHS and CMS, as this was an important step in our commitment to ensuring access and empowering patients to benefit from our advanced solutions in vascular health,\" stated Rob Fia, CEO of Therma Bright Inc. In perfect alignment with these pivotal discussions, and in anticipation of a successful and final decision in August 2023, Therma Bright has continued to expand its U.S.-based distribution network and commercialization under the current nine (9) temporary CPT and HCPCS codes. This expansion provides nationwide commercial access to clinical groups and hospital systems that are excited to provide widespread availability of the Venowave device to patients suffering from vascular disorders.\"The State of Texas has exhibited an exceptional demand for our Venowave particularly among Orthopedic and Podiatry groups, with the Dallas Fort Worth region leading the way,\" continued Rob Fia, CEO. \"The staggering volumes of patients these groups are currently handling with vascular disorders are projected to result in the prescription of an impactful number of our Venowave solution on a monthly basis.\"Therma Bright firmly believes that although commercialization efforts under the temporary CPT and HCPCS codes may be of a transient nature, the outcomes from its most recent commercialization endeavors in the State of Texas are expected to materialize over upcoming quarters. The Company anticipates remarkable success and significa...